Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
NCT00144508 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 306
Last updated 2009-02-02
Summary
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
Conditions
Interventions
- DRUG
-
MRA (Tocilizumab)
8mg /kg /4week for 52 weeks
- OTHER
-
current treatment
continue current treatment
Sponsors & Collaborators
-
Chugai Pharmaceutical
lead INDUSTRY
Principal Investigators
-
Takahiro Kakehi · Chugai Pharmaceutical
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-03-31
- Primary Completion
- 2004-05-31
- Completion
- 2006-02-28
More Related Trials
-
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
NCT00144534 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
NCT00144573 ·Status: COMPLETED ·Phase: NA
-
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
NCT00144560 ·Status: COMPLETED ·Phase: NA
-
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144599 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144612 ·Status: COMPLETED ·Phase: PHASE3
-
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144664 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144625 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01347983 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NCT00720798 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01258712 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis
NCT04384068 ·Status: UNKNOWN
-
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
NCT02404558 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
NCT00661284 ·Status: COMPLETED
-
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
NCT01332994 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
NCT00074438 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
NCT00721123 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Single Dose IL-6R mAb Injection in RA Patients
NCT05232396 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
NCT00891020 ·Status: COMPLETED ·Phase: PHASE3
-
Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis
NCT02837146 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
NCT01149057 ·Status: COMPLETED ·Phase: PHASE4
-
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
NCT00750880 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT00106548 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
NCT01119859 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
NCT00996203 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01211834 ·Status: COMPLETED ·Phase: PHASE3